Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NITROFURANTOIN MONO/MICRO CRYSTALS

3 general benefit · 1 not a benefit

Other products in the same Health Canada class (J01X, J01XE) — coverage varies; not interchangeable

  • Nitrofurantoin (Macrodantin): general benefit, Not a benefit
  • Fosfomycin tromethamine (Monurol): general benefit

Auro-Nitrofurantoin BID · DIN 02466392 · 100mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Nitrofurantoin BID · DIN 02466392 Manufacturer: Auro Pharma Inc.; listing date 2024-07-31 Health Canada: Marketed since 2020-09-09 · brand AURO-NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3067 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95474 · Verify on the e-Formulary ↗ (DIN 02466392)

Source record
DIN 02466392: Auro-Nitrofurantoin BID Raw flags: sec3=Y Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id AUR Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.3067; ministry $0.3067 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95474
Interchangeable products
Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067 MacroBID · DIN 02063662 · not recorded PMS-Nitrofurantoin BID · DIN 02455676 · $0.3067
Shortage status: resolved shortage (ended 2025-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466392
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Nitrofurantoin BID · DIN 02544954 · 100mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Nitrofurantoin BID · DIN 02544954 Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30 Health Canada: Marketed since 2025-02-18 · brand JAMP NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3067 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103357 · Verify on the e-Formulary ↗ (DIN 02544954)

Source record
DIN 02544954: Jamp Nitrofurantoin BID Raw flags: sec3=Y Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id JPC Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.3067; ministry $0.3067 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544954 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103357
Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067 MacroBID · DIN 02063662 · not recorded PMS-Nitrofurantoin BID · DIN 02455676 · $0.3067
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544954
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Nitrofurantoin BID · DIN 02455676 · 100mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Nitrofurantoin BID · DIN 02455676 Manufacturer: Pharmascience Inc.; listing date 2018-07-31 Health Canada: Marketed since 2021-08-11 · brand PMS-NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3067 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94248 · Verify on the e-Formulary ↗ (DIN 02455676)

Source record
DIN 02455676: PMS-Nitrofurantoin BID Raw flags: sec3=Y Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id PMS Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.3067; ministry $0.3067 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455676 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94248
Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067 Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067 MacroBID · DIN 02063662 · not recorded
Shortage status: active shortage (reported 2026-08-21, estimated to end 2027-01-05, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455676
Shortage record checked 2026-09-13T08:10:21.292534+00:00

MacroBID · DIN 02063662 · 100mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.Discontinued 2021-08-12 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
MacroBID · DIN 02063662 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-12-19 Health Canada: Cancelled post market since 2021-08-12 · brand MACROBID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Allergan inc · schedule Prescription
Check this DIN again · Health Canada product record

MacroBID: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15173 · Verify on the e-Formulary ↗ (DIN 02063662)

Source record
DIN 02063662: MacroBID Raw flags: notABenefit=Y, sec3=Y Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id WAR Source form: Cap; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02063662 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15173
Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067 Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067 PMS-Nitrofurantoin BID · DIN 02455676 · $0.3067
Shortage status: discontinued (2021-08-13, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02063662
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:36 Urinary Anti-Infectives) and how they are covered

Matched class: 08:36 Urinary Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FOSFOMYCIN TROMETHAMINE Some products covered without a code (check the product listing): NITROFURANTOIN 08:36 Urinary Anti-Infectives

NITROFURANTOIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 50mg, 100mg · Cap, Tab

FOSFOMYCIN TROMETHAMINE

· 2 products · General benefit · strengths: · Sachet-3g Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:36
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pms-NITROFURANTOIN BID is indicated for the treatment of acute uncomplicated urinary tract infections, e.g., cystitis, when due to susceptible strains of Escherichia coli, and Staphylococcus saprophyticus. pms-NITROFURANTOIN BID is not indicated for the treatment of associated renal cortical or perinephric abscesses. pms-NITROFURANTOIN BID is not indicated for therapy of any systemic infections or for use in prostatitis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of pms-NITROFURANTOIN BID and other antibacterial drugs, pms-NITROFURANTOIN BID pms-NITROFURANTOIN BID Product Monograph Page 2 of 21 should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. https://pdf.hres.ca/dpd_pm/00057835.PDF PM date: August 26, 2020 Source product: PMS-NITROFURANTOIN BID; DIN 02455676; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Nitrofurantoin BID · DIN 02455676 Shortage status: active shortage (reported 2026-08-21, estimated to end 2027-01-05, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455676

Check this DIN again

MacroBID · DIN 02063662 Shortage status: discontinued (2021-08-13, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02063662

Check this DIN again

Other review policies

For MacroBID: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026